The Vanguard Group, Inc. recently announced the acquisition of new stake in Jaguar Health Inc (NASDAQ:JAGX). The institutional investor has increased its shareholding in the Healthcare company by 142.35% to 0.19 million shares with purchase of 0.11 million shares. This fresh investment now brings its stake to 0.38% valued currently at $68087.0. In addition, JPMorgan Securities LLC raised its holdings by 62401.0 to 85384.0 shares. And Sterling Investment Advisors Ltd. has lifted its position by 105.26% or 20000.0 shares – to 39000.0 shares.
With over 6.46 million Jaguar Health Inc (JAGX) shares trading Tuesday and a closing price of $0.12 on the day, the dollar volume was approximately $0.77 million. The shares have shown a negative half year performance of -78.00% and its price on 01/09/24 lost nearly -8.19%. Currently, there are 50.76M common shares owned by the public and among those 40.48M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 24 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 24 of these insider trades were purchases, accounting for 1,379,865 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Jaguar Health Inc are Fidelity Extended Market Index Fu, Vanguard Extended Market Index Fu, and Fidelity Nasdaq Composite Index F. Fidelity Extended Market Index Fu owns 0.34 million shares of the company’s stock, all valued at over $0.12 million. Fidelity Nasdaq Composite Index F bought 28572.0 shares to bring its total holdings to over 29099.0 shares at a value of $10301.0. Fidelity Nasdaq Composite Index F now owns shares totaling to 0.06% of the shares outstanding.
However, the script later moved the day high at 0.1300, down -8.19%. The company’s stock has a 5-day price change of -21.43% and -51.45% over the past three months. JAGX shares are trading -21.53% year to date (YTD), with the 12-month market performance down to -98.20% lower. It has a 12-month low price of $0.13 and touched a high of $9.15 over the same period. JAGX has an average intraday trading volume of 6.73 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -26.75%, -55.66%, and -74.25% respectively.
Institutional ownership of Jaguar Health Inc (NASDAQ: JAGX) shares accounts for 1.16% of the company’s 50.76M shares outstanding. Mutual fund holders own 1.11%, while other institutional holders and individual stakeholders account for 2.76% and 0.05% respectively.
It has a market capitalization of $6.03M and a beta (3y monthly) value of 1.40. The earnings-per-share (ttm) stands at -$6.88. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.57% over the week and 10.50% over the month.
Analysts forecast that Jaguar Health Inc (JAGX) will achieve an EPS of $Argan, Inc. for the current quarter, $45.42 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Janus Henderson Growth and Inco while analysts give the company a high EPS estimate of $Janux Therapeutics, Inc.. Comparatively, EPS for the current quarter was $Janus Henderson Global Technolo a year ago. EPS should shrink at an annualized rate of 40.00% over the next five years, compared to 80.25% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Jaguar Health Inc (JAGX) as a “Strong Buy” at a consensus score of 1.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the JAGX, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on July 07, 2021, with the firm’s price target at $5.
